Cullinan Therapeutics to present new results from REZILIENT1 trial
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the . Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target. A healthcare professional discussing treatment options for a patient with a neurological disorder. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders. Operating from its headquarters in California, the company gained U.S. approval for valbenazine (Ingrezza®) for tardive dyskinesia and markets treatments for Huntington's chorea, adrenal hyperplasia, endometriosis, and uterine fibroids. The company's comprehensive pipeline includes treatments for Parkinson's, Tourette's, and novel agents like NBI‑1117568 in schizophrenia trials. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the termination of its Phase 2 study on NBI-921352, an investigational drug, as of July 14, 2025. The company, with its tests, aimed to evaluate the safety and tolerability of the drug when used alongside other treatments for patients with SCN8A-DEE, a rare and severe neurological disorder. Phase 2 of the study involved assessing the drug's ability to reduce seizure frequency in patients with SCN8A-DEE. As it failed to show a meaningful reduction, the study was terminated. The company's lead candidates continue to be crinecerfont for congenital adrenal hyperplasia (CAH), and NBI-1117568, a potential treatment for psychosis and cognitive disorders. Later, on July 21, 2025, Truist initiated coverage of the stock with a Buy rating and a price target of $163. On the other hand, Morgan Stanley, while maintaining the Buy rating, has raised the price target from $148 to $150. Despite the trial setback, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) continues to show strong growth prospects with a 33.73% projected EPS increase and a low beta of 0.25. While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Sign in to access your portfolio
Yahoo
6 days ago
- Yahoo
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Updated efficacy data will be presented from the REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who were previously treated with amivantamab Preliminary findings to be shared from the cohort of patients with uncommon non-ex20ins EGFR mutations enrolled in the REZILIENT2 trial of zipalertinib PRINCETON, N.J. and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of Lung Cancer's (IASLC) 2025 World Conference on Lung Cancer (WCLC), to be held September 6-9, 2025, in Barcelona, Spain. The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 trial, focusing on patients with EGFR ex20ins NSCLC previously treated with amivantamab, as well as the preliminary efficacy and safety results from the Phase 2 parallel cohort REZILIENT2 trial in patients with advanced or metastatic NSCLC harboring uncommon non-ex20ins EGFR mutations. "Previously, zipalertinib has demonstrated clinical activity against ex20ins and preclinical activity against uncommon, non-ex20ins EGFR-mutant NSCLC," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. "We look forward to sharing updated data from the REZILIENT1 and REZILIENT2 trials at the upcoming 2025 World Conference on Lung Cancer, suggesting the potential for zipalertinib to make a meaningful difference in the lives of patients with certain types of NSCLC." "Despite advances in the treatment landscape, there remains significant unmet need for NSCLC patients with EGFR exon 20 insertion mutations and for those with uncommon non-ex20ins EGFR mutations," said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. "Taken together, the updated results from REZILIENT1 and new data from the REZILIENT2 study highlight the potential of zipalertinib to play an important role in the evolving treatment landscape for patients with NSCLC harboring less common EGFR mutations." Session titles and information for the two abstracts are listed below. Full abstract details will be available via the conference website at 1 p.m. EDT August 13, 2025. Title: Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab Session Name: MA08 - Common and Uncommon EGFR Mutations, New Treatments in the HorizonSession Type: Mini Oral PresentationSession Date: Tuesday, September 9, 2025Session Time: 11:30 a.m. – 12:45 p.m. CESTPresenter: Zofia Piotrowska, MD Title: Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR MutationsSession Name: MA08 - Common and Uncommon EGFR Mutations, New Treatments in the Horizon Session Type: Mini Oral PresentationSession Date: Tuesday, September 9, 2025Session Time: 11:30 a.m. – 12:45 p.m. CESTPresenter: Hibiki Udagawa, MD, PhD About ZipalertinibZipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib has received Breakthrough Therapy Designation from the FDA. Zipalertinib is investigational and has not been approved by any health authority. Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S. About Taiho Oncology, mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada. For more information, visit and follow us on LinkedIn and X. Taiho Oncology and the Taiho Oncology logo are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries. About Cullinan TherapeuticsCullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at and follow us on LinkedIn and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company's beliefs and expectations regarding our plans regarding future data presentations, the clinical development and regulatory filing plan and timeline of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, and other statements that are not historical facts. The words "believe," "continue," "could," "estimate," "expect," "intends," "may," "plan," "potential," "project," "pursue," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any NDA or other regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Contacts Taiho OncologyLeigh Labrie+1 609.664.9878 LLabrie@ Cullinan TherapeuticsInvestorsNick Smith+1 401.241.3516nsmith@ Media Rose Weldon +1 215.801.7644 rweldon@ View original content to download multimedia: SOURCE Taiho Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
17-07-2025
- Associated Press
Lobe Sciences Ltd. Announces Debt Settlement
VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that it has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for legal services previously provided to the Company. In satisfaction of this obligation, Lobe has issued 546,206 common shares of the Company to Gibbson Law P.C. at a deemed price of CAD$0.02123 per share. The shares were issued on May 13, 2025, and are subject to applicable regulatory hold periods under Canadian securities laws. About Lobe Sciences - Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) is a biopharmaceutical company focused on developing innovative therapies for rare and underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and its majority-owned subsidiary, Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based platform for treating Sickle Cell Disease and a novel oral analog of psilocin-Conjugated Psilocin™-targeted at Chronic Cluster Headache and other neurological disorders. These programs address significant unmet medical needs with the potential to improve outcomes in both hematologic and neuropsychiatric patient populations. For further information: Dr. Fred D. Sancilio, CEO Lobe Sciences Ltd. Investor and Media [email protected] Phone: +1 (949) 505-5623 Cautionary Statement Regarding 'Forward-Looking' Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company's intention to raise funds for clinical trials, the innovativeness of Conjugated Psilocin™. the anticipated focus and timing or efficiency of the Company's research and development activities; the potential for the Company's products to meet unmet medical needs, the anticipated use of proceeds from the offering, the intended development plans for Cynaptec™, the intention of Lobe Sciences to provide certain services to Cynaptec, the potential exercise of the option and intended use of proceeds therefrom and the potential ability to raise funds for clinical development are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as 'intends' or 'anticipates', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'should' or 'would' or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company's planned activities will be able to create shareholder value and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities, and that the Company will be able to raise funds among others. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company's planned activities will be unable to create shareholder value or address the targeted unmet medical needs; the Company is unable to obtain the desired results from its current research and development activities; and the Company is unable to raise funds or to do so on the timelines anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE. SOURCE: Lobe Sciences Ltd. press release
